Company intelligence / Profile preview

Vasorum

Dublin, Leinster, Irelandvasorum.ie ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Vasorum’s Celt ACD® platform has been used in over 300,000 patients globally with strong clinical outcomes including rapid hemostasis and fast patient discharge. The next-generation Celt ACD® PLUS System received FDA approval in March 2025 and features Blood Signal technology to further enhance safety and efficiency of arterial closure. Clinical data show average time to hemostasis of 0.1 minute, ambulation at 18.3 minutes, and discharge at 38.4 minutes post-procedure.

Therapeutic areas: CardiovascularWomen's Health
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Veryan Medical – U.S. commercialization partnership for the Celt ACD device.

Beyond the preview

Go deeper on Vasorum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vasorum.

Explore the full profile